Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Hematopoietic and Lymphatic System Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Hematopoietic and Lymphatic System Neoplasm

Cancer Family

Hematopoietic and Lymphatic System Neoplasm

CI-CAN-00000022Explore in graph →

Non-malignant4,304 active trials98 approved drugs1,010 evidence items

NCIt: C35813

Overview
Statistics
Survival
Genomics60
Variants & evidence1010
Drugs99
Trials18827
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (736)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 676–700 of 736 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.
· Nat Chem Biol · 2015 · PMID 26436839 · validated civic_curation pubmed
The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma.
· Cell Death Differ · 2014 · PMID 24013721 · validated civic_curation pubmed
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
· Blood · 2013 · PMID 23430109 · validated civic_curation pubmed
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
· Cancer Res · 2009 · PMID 19318574 · validated civic_curation pubmed
Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia.
· Nat Chem Biol · 2015 · PMID 26167872 · validated civic_curation pubmed
Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.
· Exp Hematol · 2014 · PMID 24407160 · validated civic_curation pubmed
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.
· Mol Cancer Ther · 2010 · PMID 20124459 · validated civic_curation pubmed

Showing 676–700 of 736 publications

← Previous
1
…
27
28
29
30
Next →

Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations.

· Exp Hematol · 2014 · PMID 24333121 · validated civic_curation pubmed

Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.

· Leuk Res · 2008 · PMID 18191450 · validated civic_curation pubmed

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations.

· Blood · 2006 · PMID 16772610 · validated civic_curation pubmed

Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518.

· Blood · 2004 · PMID 15256420 · validated civic_curation pubmed

Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.

· Blood · 2004 · PMID 15304385 · validated civic_curation pubmed

AS602868, a dual inhibitor of IKK2 and FLT3 to target AML cells.

· Leukemia · 2007 · PMID 17330097 · validated civic_curation pubmed

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance.

· Proc Natl Acad Sci U S A · 2005 · PMID 15705718 · validated civic_curation pubmed

Integrated molecular analysis of adult T cell leukemia/lymphoma.

· Nat Genet · 2015 · PMID 26437031 · validated civic_curation pubmed

PDGFRB mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.

· Blood · 2018 · PMID 29434033 · validated civic_curation pubmed

Sensitivity of SNX2-ABL1 toward tyrosine kinase inhibitors distinct from that of BCR-ABL1.

· Leuk Res · 2014 · PMID 24367893 · validated civic_curation pubmed

Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3-Positive Acute Myeloid Leukemia.

· Mol Cancer Ther · 2018 · PMID 29237803 · validated civic_curation pubmed

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.

· Nat Commun · 2019 · PMID 31160589 · validated civic_curation pubmed

Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

· Blood · 2004 · PMID 15178581 · validated civic_curation pubmed

Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor.

· Blood · 2017 · PMID 27908881 · validated civic_curation pubmed

The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma.

· Am J Cancer Res · 2016 · PMID 27904766 · validated civic_curation pubmed

Cancer-Associated SF3B1 Mutations Confer a BRCA-Like Cellular Phenotype and Synthetic Lethality to PARP Inhibitors.

· Cancer Res · 2022 · PMID 35027467 · validated civic_curation pubmed

Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.

· Nat Commun · 2019 · PMID 31784538 · validated civic_curation pubmed

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

· Cancer Cell · 2007 · PMID 18068628 · validated civic_curation pubmed